News Column

Study Results from University of Turku Broaden Understanding of Cardiovascular Research (Injected nanoparticles: The combination of experimental...

August 1, 2014



Study Results from University of Turku Broaden Understanding of Cardiovascular Research (Injected nanoparticles: The combination of experimental systems to assess cardiovascular adverse effects)

By a News Reporter-Staff News Editor at Drug Week -- Current study results on Cardiovascular Research have been published. According to news reporting from Turku, Finland, by NewsRx journalists, research stated, "When nanocarriers are used for drug delivery they can often achieve superior therapeutic outcomes over standard drug formulations. However, concerns about their adverse effects are growing due to the association between exposure to certain nanosized particles and cardiovascular events."

The news correspondents obtained a quote from the research from the University of Turku, "Here we examine the impact of intravenously injected drug-free nanocarriers on the cardiovasculature at both the systemic and organ levels. We combine in vivo and in vitro methods to enable monitoring of hemodynamic parameters in conscious rats, assessments of the function of the vessels after sub-chronic systemic exposure to nanocarriers and evaluation of the direct effect of nanocarriers on vascular tone. We demonstrate that nanocarriers can decrease blood pressure and increase heart rate in vivo via various mechanisms. Depending on the type, nanocarriers induce the dilation of the resistance arteries and/or change the responses induced by vasoconstrictor or vasodilator drugs. No direct correlation between physicochemical properties and cardiovascular effects of nanoparticles was observed."

According to the news reporters, the research concluded: "The proposed combination of methods empowers the studies of cardiovascular adverse effects of the nanocarriers."

For more information on this research see: Injected nanoparticles: The combination of experimental systems to assess cardiovascular adverse effects. European Journal of Pharmaceutics and Biopharmaceutics, 2014;87(1):64-72. European Journal of Pharmaceutics and Biopharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutics and Biopharmaceutics - www.elsevier.com/wps/product/cws_home/600120)

Our news journalists report that additional information may be obtained by contacting M.A. Vlasova, University of Turku, Dept. of Phys & Astron, Turku, Finland. Additional authors for this research include O.S. Tarasova, J. Riikonen, J. Raula, A.S. Lobach, A.A. Borzykh, B.V. Smirin, E.I. Kauppinen, A.V. Eletskii, K.H. Herzig, J. Salonen, P. Tavi, V.P. Lehto and K. Jarvinen (see also Cardiovascular Research).

Keywords for this news article include: Turku, Finland, Europe, Cardiology, Cardiovascular, Cardiovascular Research, Emerging Technologies, Nanocarriers, Nanoparticle, Nanotechnology

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters